Lonza Group (LONN) Stock Overview
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LONN Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 538.40 |
| 52 Week High | CHF 597.80 |
| 52 Week Low | CHF 454.60 |
| Beta | 0.84 |
| 1 Month Change | -4.94% |
| 3 Month Change | 9.52% |
| 1 Year Change | -1.36% |
| 3 Year Change | 22.17% |
| 5 Year Change | -28.91% |
| Change since IPO | 486.49% |
Recent News & Updates
Should You Be Adding Lonza Group (VTX:LONN) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside
Lonza Group's updated analyst price target edges higher to CHF 678, supported by broader target increases across the Street toward CHF 640 to CHF 760 as analysts factor in revised assumptions on fair value, discount rate, revenue growth, profit margin and future P/E levels. Analyst Commentary Recent research on Lonza Group points to a mixed but generally constructive stance, with several price target adjustments clustering between CHF 590 and CHF 760.Recent updates
Should You Be Adding Lonza Group (VTX:LONN) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside
Lonza Group's updated analyst price target edges higher to CHF 678, supported by broader target increases across the Street toward CHF 640 to CHF 760 as analysts factor in revised assumptions on fair value, discount rate, revenue growth, profit margin and future P/E levels. Analyst Commentary Recent research on Lonza Group points to a mixed but generally constructive stance, with several price target adjustments clustering between CHF 590 and CHF 760.LONN: Bioprocessing Recovery And ADC Licensing Pipeline Will Drive Future Upside
Analysts have trimmed their average price target for Lonza Group to roughly CHF 663 from about CHF 664, reflecting slightly higher discount rate assumptions and updated expectations for revenue growth, profit margins, and future P/E multiples in light of recent research that includes reduced targets of CHF 590 and CHF 656 from major banks. Analyst Commentary Recent research on Lonza Group shows that analysts are adjusting their models and price targets while still weighing the company against broader views on life science tools, bioprocessing and quality assurance demand.LONN: Recovery In Life Science Tools Demand Will Drive Future Upside
Narrative Update: Lonza Group Analysts have trimmed their blended price target for Lonza Group by about CHF 13 to reflect lower fair value estimates and a higher discount rate, even as they point to early signs of recovery in life science tools demand and resilient profitability expectations. Analyst Commentary Recent research updates show that price targets for Lonza Group have been revised lower, even as some analysts highlight early recovery signs in key end markets.Lonza Group's (VTX:LONN) Solid Earnings Are Supported By Other Strong Factors
Lonza Group AG ( VTX:LONN ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...Is There Now An Opportunity In Lonza Group AG (VTX:LONN)?
Lonza Group AG ( VTX:LONN ) saw significant share price movement during recent months on the SWX, rising to highs of...We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Investors Interested In Lonza Group AG's (VTX:LONN) Earnings
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...Vacaville And Visp Facilities Will Secure Future Biologics Demand
Given the absence of analyst reasoning, the consensus analyst price target for Lonza Group saw only a marginal increase from CHF665.36 to CHF676.18 alongside minimal changes in key valuation metrics such as future P/E and discount rate, indicating steady market expectations and a broadly unchanged fair value outlook. What's in the News Lonza entered a seven-year manufacturing agreement with Avidity Biosciences for commercial drug substance and product, with a minimum purchase commitment of approximately $620 million between 2026 and 2028.
CDMO Focus And Vacaville Acquisition To Drive Operational Improvements By 2025
Focus on CDMO business and Vacaville acquisition to drive revenue growth and boost sales.Shareholder Returns
| LONN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0.07% | -2.2% | -1.9% |
| 1Y | -1.4% | 2.1% | 12.6% |
Return vs Industry: LONN underperformed the Swiss Life Sciences industry which returned 2.1% over the past year.
Return vs Market: LONN underperformed the Swiss Market which returned 12.6% over the past year.
Price Volatility
| LONN volatility | |
|---|---|
| LONN Average Weekly Movement | 3.2% |
| Life Sciences Industry Average Movement | 5.3% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: LONN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: LONN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 20,141 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.
Lonza Group AG Fundamentals Summary
| LONN fundamental statistics | |
|---|---|
| Market cap | CHF 37.52b |
| Earnings (TTM) | CHF 1.08b |
| Revenue (TTM) | CHF 6.87b |
Is LONN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LONN income statement (TTM) | |
|---|---|
| Revenue | CHF 6.87b |
| Cost of Revenue | CHF 4.32b |
| Gross Profit | CHF 2.55b |
| Other Expenses | CHF 1.47b |
| Earnings | CHF 1.08b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.48 |
| Gross Margin | 37.14% |
| Net Profit Margin | 15.73% |
| Debt/Equity Ratio | 51.1% |
How did LONN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 17:33 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lonza Group AG is covered by 53 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| "Charles Pitman-King | Barclays |
| Xian Deng | Berenberg |